Neurohormonal Regulators of Obesity: Mediating Weight Loss Through Peptide Hormone Therapeutics CME

Samuel Klein, MD; Louis Aronne, MD; Ken Fujioka, MD; Michael Schwartz, MD Author Information and Disclosures

Release Date: February 13, 2008; Valid for credit through February 13, 2009

Credits Available
Physicians - maximum of 1.5 AMA PRA Category 1 Credit(s)™ for physicians

To participate in this activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details

Contents of This CME Activity

  1. Why Can't People Lose Weight?Samuel Klein, MD; Ken Fujioka MD Available As: Slides/Audio | Slides/Transcript | Audio
  2. Neurohormonal Regulation of Energy BalanceMichael Schwartz, MD Available As: Slides/Audio | Slides/Transcript | Audio
  3. Advances in Neurohormonal Therapy in the Treatment of ObesityLouis J. Aronne, MD Available As: Slides/Audio | Slides/Transcript | Audio

Legal Disclaimer

The material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

Copyright © 2008 Vindico Medical Education
Amylin
Learning Objectives

Upon completion of this activity, participants should be better able to:

  1. Describe the most current understanding of obesity pathophysiology.
  2. Identify and describe the neurohormonal regulators of obesity.
  3. Evaluate the latest clinical data impacting the management of obesity with peptide hormone therapeutics.
Authors and Disclosures

Samuel Klein, MD
Disclosure: Consultant: sanofi-aventis. Grant Research: sanofi-aventis


Louis J. Aronne, MD
Disclosure: Speakers' Bureau: Pfizer, sanofi-aventis. Consultant: sanofi-aventis, Merck, Pfizer, Amylin, Genaera, Orexigen. Grant Research: Amylin, sanofi-aventis, Merck, Pfizer, Medtronic, Orexigen, Obecure, Metacure Inc., Arena.


Ken Fujioka, MD
Disclosure: Consultant: Amylin. Grant Research: Amylin, Sanofi


Michael Schwartz, MD
Disclosure: Speakers' Bureau: Takeda Pharmaceuticals North America. Consultant: Cypress Bioscience Inc, Essentialis, Shionogi USA, Merck.


 
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Vindico Medical Education designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Contact This Provider

All material on this website is protected by copyright, Copyright © 1994-2008 by Medscape. This website also contains material copyrighted by 3rd parties.